Condition
PSA
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 13 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownAnti-inflammatory Drugs and Serum Prostate-Specific Antigen TestNCT05629494 · 2022-09-27
RECRUITINGEDRN Prostate MRI Biomarker StudyNCT03784924 · 2019-02-04
RECRUITINGSmart Prostate Specific Antigen (PSA) Screening StudyNCT04782713 · 2021-12-17
COMPLETEDDarolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMANCT04319783 · 2021-06-02
ACTIVE_NOT_RECRUITINGPSA Glycomics Assay for Early Detection of Prostate CancerNCT04393376 · 2020-08-01
UNKNOWNMarker Driven Selection of Patients for Prostate Biopsy and ManagementNCT04240327 · 2020-06-29
ACTIVE_NOT_RECRUITINGRegisterPROS - A Registry for Prostate CancersNCT06872619 · 2020-01-15
ENROLLING_BY_INVITATIONPrediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPVNCT04251546 · 2020-01-04
UNKNOWNProstate Biopsy, Transrectal vs. Transperineal: Efficacy and ComplicationsNCT04081636 · 2019-09-02
COMPLETEDMRI Prostate for Chinese Men Being Screened for Prostate CancerNCT03891732 · 2019-01-19
ACTIVE_NOT_RECRUITINGProstate Impendance Test ProjectNCT03428087 · 2017-07-01
UNKNOWNPromoting CSD500 Use Among Women in Established RelationshipsNCT02934620 · 2017-06-09
COMPLETEDOGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving AbirateroneNCT01681433 · 2012-12-01
TERMINATEDCommon interventions
MRI prostateDIAGNOSTIC_TEST2Abiraterone AcetateDRUG1Completing surveysOTHER1Condom CounselingBEHAVIORAL1CSD500 CondomDEVICE1DarolutamideDRUG1Ibuprofen 400 mg, TIDDRUG1OGX-427DRUG1p2PSADIAGNOSTIC_TEST1PrednisoneDRUG1PROSTestDEVICE1PSA Glycomics AssayDIAGNOSTIC_TEST1PSA testDIAGNOSTIC_TEST1RadiotherapyRADIATION1Standard CondomDEVICE1Systematic Transperineal biopsy (TP-Bx)PROCEDURE1Systematic Transrectal biopsy (TR-Bx)PROCEDURE1Targeted Transperineal biopsy (TP-Bx)PROCEDURE1Targeted Transrectal biopsy (TR-Bx)PROCEDURE1Transperineal prostate biopsyDIAGNOSTIC_TEST1Ultrasonic parametersDIAGNOSTIC_TEST1
Leading sponsors
Albany Medical College
2
Chinese University of Hong Kong
1
Costantine Albany
1
Ohio State University
1
Prof.dr. H.P. Beerlage
1
Trans Tasman Radiation Oncology Group
1
University of Illinois at Chicago
1
University of Miami
1
University of Michigan
1
University of Pisa
1
Wren Laboratories LLC
1
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
1
Trial status mix
ACTIVE_NOT_RECRUITING3
COMPLETED3
UNKNOWN3
RECRUITING2
ENROLLING_BY_INVITATION1
TERMINATED1
Phase mix
NA4
PHASE22
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.